Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -11.67 Million SEK | 27.75% |
| 2022 | -16.16 Million SEK | -38.59% |
| 2021 | -11.66 Million SEK | -1899.28% |
| 2020 | -583.36 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.44 Million SEK | -15.09% |
| 2024 Q3 | -1.24 Million SEK | 63.92% |
| 2024 Q1 | -2.98 Million SEK | -18.14% |
| 2023 Q2 | -2.79 Million SEK | 24.21% |
| 2023 FY | -11.67 Million SEK | 27.75% |
| 2023 Q4 | -2.53 Million SEK | 4.78% |
| 2023 Q1 | -3.69 Million SEK | 11.82% |
| 2023 Q3 | -2.65 Million SEK | 5.04% |
| 2022 FY | -16.16 Million SEK | -38.59% |
| 2022 Q4 | -4.18 Million SEK | -11.45% |
| 2022 Q3 | -3.75 Million SEK | 22.47% |
| 2022 Q2 | -4.84 Million SEK | -43.54% |
| 2022 Q1 | -3.37 Million SEK | 5.33% |
| 2021 Q2 | -3.06 Million SEK | -321.73% |
| 2021 FY | -11.66 Million SEK | -1899.28% |
| 2021 Q3 | -4.3 Million SEK | -40.38% |
| 2021 Q4 | -3.56 Million SEK | 17.15% |
| 2021 Q1 | -727 Thousand SEK | -73.37% |
| 2020 Q4 | -419.33 Thousand SEK | -430.8% |
| 2020 Q2 | -278 Thousand SEK | -3871.43% |
| 2020 Q1 | -7000.00 SEK | 0.0% |
| 2020 FY | -583.36 Thousand SEK | 0.0% |
| 2020 Q3 | -79 Thousand SEK | 71.58% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | 29.138% |
| Amniotics AB (publ) | -30.87 Million SEK | 62.17% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 8.965% |
| BioArctic AB (publ) | 229.24 Million SEK | 105.094% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 97.495% |
| Saniona AB (publ) | -95.81 Million SEK | 87.811% |
| Simris Alg AB (publ) | -37.3 Million SEK | 68.696% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 96.244% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 44.63% |
| NextCell Pharma AB | -41.95 Million SEK | 72.169% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 28.784% |
| AcouSort AB (publ) | -17.08 Million SEK | 31.664% |
| Active Biotech AB (publ) | -45.8 Million SEK | 74.502% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 95.302% |
| Camurus AB (publ) | 431.44 Million SEK | 102.707% |
| Cantargia AB (publ) | -280.02 Million SEK | 95.83% |
| Genovis AB (publ.) | 61.5 Million SEK | 118.989% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 89.695% |
| Mendus AB (publ) | -101.61 Million SEK | 88.508% |
| Kancera AB (publ) | -64.88 Million SEK | 82.003% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 316.821% |
| LIDDS AB (publ) | -40.2 Million SEK | 70.955% |
| Lipum AB (publ) | -37.17 Million SEK | 68.589% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 3.71% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 195.965% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 34.749% |
| OncoZenge AB (publ) | -15.9 Million SEK | 26.563% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 96.992% |
| Xintela AB (publ) | -54.08 Million SEK | 78.407% |
| Ziccum AB (publ) | -21.41 Million SEK | 45.46% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 68.498% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 93.5% |
| CombiGene AB (publ) | -35.66 Million SEK | 67.257% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 92.31% |
| Intervacc AB (publ) | -102.85 Million SEK | 88.646% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -2566.21% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 29.323% |
| Corline Biomedical AB | -1.8 Million SEK | -545.55% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 93.433% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 79.448% |
| Aptahem AB (publ) | -11.11 Million SEK | -5.085% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 90.511% |
| Fluicell AB (publ) | -26.55 Million SEK | 56.022% |
| Biovica International AB (publ) | -124.82 Million SEK | 90.644% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 72.342% |
| Abliva AB (publ) | -95.5 Million SEK | 87.773% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 96.428% |
| 2cureX AB (publ) | -32.51 Million SEK | 64.088% |
| I-Tech AB | 20.2 Million SEK | 157.803% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.596% |
| Cyxone AB (publ) | -22.98 Million SEK | 49.202% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 87.223% |
| Biosergen AB | -27.03 Million SEK | 56.807% |
| Nanologica AB (publ) | -75.15 Million SEK | 84.462% |
| SynAct Pharma AB | -215.81 Million SEK | 94.589% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 73.492% |
| BioInvent International AB (publ) | -330.3 Million SEK | 96.464% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 50.803% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 95.312% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -17.603% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 89.314% |